SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
FDA
After Prasad’s Ouster, Makary Looks for Better Drug, Biologic Alignment at FDA
The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research into one entity.
August 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Earnings
‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring
In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.
August 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Merck’s $3B Savings Push Claims 6,000 Jobs
Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth areas of its business.
August 1, 2025
 · 
1 min read
 · 
Tristan Manalac
President Donald Trump signs S.1852, The GENIUS Act, Friday, July 18, 2025, in the East Room of the White House. (Official White House Photo by Daniel Torok)
Drug pricing
Trump Asks Big Pharmas To Move on Most Favored Nation Drug Pricing—Or Else
In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the government ‘will deploy every tool in our arsenal to protect American families from continued drug pricing practices.’
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Facade of the FDA's office in Maryland
Regulatory
FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs
The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla. Meanwhile, the regulator turned away a cell therapy for Duchenne muscular dystrophy and a gene therapy for the rare disease Sanfilippo syndrome.
July 31, 2025
 · 
10 min read
 · 
Tristan Manalac
Problems and Challenges. Businessman stands on question mark
Earnings
Future of BMS’ Cobenfy Still in Limbo After Phase III Fail
Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase III ARISE study, which earlier this year failed to demonstrate significant symptom improvement.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Protection From Tariffs as an An umbrella that shields against import and export tariff taxes as a trade war storm increasing prices and straining supply chains as a business metaphor and a symbol for resilience in times of crisis and economic downturn.
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
 · 
2 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Businessman pushing boulder uphill vector concept of Sisyphus. Symbol of hard work, futile effort, strength, struggle, challenge but also motivation and ambition. Eps10 vector illustration.
Earnings
Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock
Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.
July 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS